BCIQ Profiles

Company Profile Report

$145M raise positions Rallybio to bring first rare disease program into clinic

Pivotal bioVenture leads megaround for biotech helmed by Alexion veterans

With its series A funds deployed to acquire three rare disease programs, Rallybio has raised a $145 million series B led by Pivotal bioVenture Partners to bring the first of those candidates into the clinic next half, and to continue its in-licensing spree.

Fellow new investors including Viking Global Investors, TPG Capital’s The Rise Fund, F-Prime Capital, funds managed by

Read the full 593 word article

How to gain access

Continue reading with a
two-week free trial.